The group said the move was spurred by its commitment to evidence-based medicine amid a landscape of conflicting public health information.
A wearable ultrasound patch can provide continuous, real-time information about blood flow in the fetus and umbilical cord, according to a study published online May 26 in Nature Biotechnology. Geonho ...
A single, once-weekly tablet could change HIV treatment landscape; weight loss drug orforglipron efficacy assessed at all stages of menopause; hemophilia ...
Gray matter volume increased by true acupoint, with increases in specific areas positively correlated with motor recovery ...
A phase 2 trial is investigating MTX-001, an injectable regenerative therapy, for patients with noninfected venous leg ulcers.
A new extended maintenance regimen for Ebglyss has been approved for eligible patients with moderate to severe atopic dermatitis.
The over-the-counter softgels are used to relieve pressure, bloating, and fullness by rapidly breaking up gas bubbles in the ...
Zasocitinib is an investigational, once-daily, highly selective oral tyrosine kinase 2 inhibitor being developed for immune-mediated inflammatory diseases.
Phase 3 ISLEND-1 and ISLEND-2 trials met primary endpoints at week 48, showing a novel, once-weekly oral single-tablet regimen is noninferior to daily B/F/TAF or standard ART.
The phase 3 trial is evaluating the long-term effects of sibeprenlimab-szsi on kidney function in adults with primary immunoglobulin A nephropathy.
The FDA linked 12 severe kidney complications to alli between 2007 and 2023, resulting in 8 hospitalizations and 5 patients requiring dialysis. The Food and Drug Administration (FDA) has updated the ...
Sanofi is stopping the phase 3 MOBILIZE clinical trial evaluating riliprubart in adult patients with chronic inflammatory demyelinating polyneuropathy who are refractory to standard therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results